About: Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Latest price: $15.97 (-0.13%)
RLYB NASDAQ Rallybio Corp
Rallybio Corp share price
Atividade de preço de RLYB
Último preço
$ 15,970
Variação (24h)
-0,02 USD (0,13%)
Volume
13.37K
Volume (média 4 sem.)
-
Abertura
$ 15,88
Variação do dia
$ 15,83 - $ 16,28
Fechamento anterior
$ 15,99
Último negócio
29 Oct, 5:39 pm GMT+0
Atrasado
29 Oct, 5:39 pm GMT+0
RLYB price performance
Atrasado
29 Oct, 5:39 pm GMT+0
quote.marketSignals